Online first
Research paper
Published online: 2024-07-10

open access

Page views 26
Article views/downloads 16
Get Citation

Connect on Social Media

Connect on Social Media

An axis involving TPX2/hsa-let-7b-5p/TMPO-AS1 promotes lung adenocarcinoma in smokers

Rajeev Nema1

Abstract

Introduction. Lung cancer, a disease with the highest morbidity and mortality rates, is associated with smoking, which highlights the need for a better understanding of prognosis-related mRNA/miRNA/lncRNA-ceRNA networks. 

Material and methods. To look at TPX2/miRNA and LncRNA expression in lung cancer tumors and healthy tissues, the study used such databases as UALCAN, OncoDB, ENCORI, KM Plotter, miRNet, and CancerMIRNome. 

Results. In lung cancer cells, the TPX2 gene is overexpressed and linked to lung squamous cell carcinoma. High TPX2 expression is significantly associated with adenocarcinoma patients (HR = 1.88; CI 1.58–2.33; p = 2.8e–13) and those with a smoking history (HR = 1.71; CI 1.32–2.22; p = 4e–05). miRNA hsa-let-7b-5p negatively correlated with TPX2 expression (–0.371), while lncRNA TMPO-AS1 positively correlated with the TPX2 axis (0.659). 

Conclusions. Smokers with lung adenocarcinoma have poorer prognosis due to elevated levels of TPX2 and TMPO- -AS1 and low levels of miRNA hsa-let-7b-5p, possibly due to the formation of TMPO-AS1 sponges. These factors contribute to aggressive growth and poor prognosis. Targeting these factors and increasing miRNA hsa-let-7b-5p could potentially improve patient prognosis by inhibiting these factors and reducing aggressive cancer growth. Further research and clinical trials are needed to validate this targeted therapy.

Article available in PDF format

View PDF Download PDF file

References

  1. Chen JW, Dhahbi J. Lung adenocarcinoma and lung squamous cell carcinoma cancer classification, biomarker identification, and gene expression analysis using overlapping feature selection methods. Sci Rep. 2021; 11(1): 13323.
  2. Xia H, Zhang H, Ruan Z, et al. Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II-III non-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory study. Signal Transduct Target Ther. 2024; 9(1): 145.
  3. Wang X, Romero-Gutierrez CW, Kothari J, et al. Prediagnosis Smoking Cessation and Overall Survival Among Patients With Non-Small Cell Lung Cancer. JAMA Netw Open. 2023; 6(5): e2311966.
  4. Wang W, Liu H, Li G. What's the difference between lung adenocarcinoma and lung squamous cell carcinoma? Evidence from a retrospective analysis in a cohort of Chinese patients. Front Endocrinol (Lausanne). 2022; 13: 947443.
  5. Pakkala S, Ramalingam SS. Personalized therapy for lung cancer: striking a moving target. JCI Insight. 2018; 3(15).
  6. Liu J, Hou S, Wang J, et al. A Prognostic 14-Gene Expression Signature for Lung Adenocarcinoma: A Study Based on TCGA Data Mining. Oxid Med Cell Longev. 2020; 2020: 8847226.
  7. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014; 511(7511): 543–550.
  8. Chen JW, Dhahbi J. Lung adenocarcinoma and lung squamous cell carcinoma cancer classification, biomarker identification, and gene expression analysis using overlapping feature selection methods. Sci Rep. 2021; 11(1): 13323.
  9. Ratti M, Lampis A, Ghidini M, et al. MicroRNAs (miRNAs) and Long Non-Coding RNAs (lncRNAs) as New Tools for Cancer Therapy: First Steps from Bench to Bedside. Target Oncol. 2020; 15(3): 261–278.
  10. Pekarek L, Torres-Carranza D, Fraile-Martinez O, et al. An Overview of the Role of MicroRNAs on Carcinogenesis: A Focus on Cell Cycle, Angiogenesis and Metastasis. Int J Mol Sci. 2023; 24(8).
  11. Zhang R, Roostalu J, Surrey T, et al. Structural insight into TPX2-stimulated microtubule assembly. eLife. 2017; 6.
  12. Zhang W, Dong J, Wu Y, et al. Integrated Bioinformatic Analysis Reveals the Oncogenic, Survival, and Prognostic Characteristics of TPX2 in Hepatocellular Carcinoma. Biochem Genet. 2024 [Epub ahead of print].
  13. Wang J, Zheng H, He H, et al. TPX2 Serves as a Cancer Susceptibility Gene and Is Closely Associated with the Poor Prognosis of Endometrial Cancer. Genetics Research. 2022; 2022: 1–14.
  14. Zhu H, Liu J, Feng J, et al. Overexpression of TPX2 predicts poor clinical outcome and is associated with immune infiltration in hepatic cell cancer. Medicine (Baltimore). 2020; 99(49): e23554.
  15. van Gijn SE, Wierenga E, van den Tempel N, et al. TPX2/Aurora kinase A signaling as a potential therapeutic target in genomically unstable cancer cells. Oncogene. 2019; 38(6): 852–867.
  16. Wei P, Zhang Nu, Xu Ye, et al. TPX2 is a novel prognostic marker for the growth and metastasis of colon cancer. J Transl Med. 2013; 11: 313.
  17. Wang J, Zheng H, He H, et al. TPX2 Serves as a Cancer Susceptibility Gene and Is Closely Associated with the Poor Prognosis of Endometrial Cancer. Genet Res (Camb). 2022; 2022: 5401106.
  18. Huang DH, Jian J, Li S, et al. TPX2 silencing exerts anti‑tumor effects on hepatocellular carcinoma by regulating the PI3K/AKT signaling pathway. Int J Mol Med. 2019; 44(6): 2113–2122.
  19. Chandrashekar DS, Bashel B, Balasubramanya SA, et al. UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia. 2017; 19(8): 649–658.
  20. Li JH, Liu S, Zhou H, et al. starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 2014; 42(Database issue): D92–D97.
  21. Győrffy B. Transcriptome-level discovery of survival-associated biomarkers and therapy targets in non-small-cell lung cancer. Br J Pharmacol. 2024; 181(3): 362–374.
  22. Chang Le, Zhou G, Soufan O, et al. miRNet 2.0: network-based visual analytics for miRNA functional analysis and systems biology. Nucleic Acids Res. 2020; 48(W1): W244–W251.
  23. Kuleshov MV, Jones MR, Rouillard AD, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 2016; 44(W1): W90–W97.
  24. Neumayer G, Belzil C, Gruss OJ, et al. TPX2: of spindle assembly, DNA damage response, and cancer. Cell Mol Life Sci. 2014; 71(16): 3027–3047.
  25. Liu Qu, Yang P, Tu K, et al. TPX2 knockdown suppressed hepatocellular carcinoma cell invasion via inactivating AKT signaling and inhibiting MMP2 and MMP9 expression. Chin J Cancer Res. 2014; 26(4): 410–417.
  26. Hu J, He Q, Tian T, et al. Transmission of Exosomal TPX2 Promotes Metastasis and Resistance of NSCLC Cells to Docetaxel. Onco Targets Ther. 2023; 16: 197–210.
  27. Wadsworth P. TPX2. Curr Biol. 2015; 25(24).
  28. Koike Y, Yin C, Sato Y, et al. TPX2 is a prognostic marker and promotes cell proliferation in neuroblastoma. Oncol Lett. 2022; 23(4): 136.
  29. Shao T, Jiang X, Bao G, et al. Comprehensive Analysis of the Oncogenic Role of Targeting Protein for Xklp2 (TPX2) in Human Malignancies. Dis Markers. 2022; 2022: 7571066.
  30. Takahashi Y, Sheridan P, Niida A, et al. The AURKA/TPX2 axis drives colon tumorigenesis cooperatively with MYC. Ann Oncol. 2015; 26(5): 935–942.
  31. Zhou F, Wang M, Aibaidula M, et al. TPX2 Promotes Metastasis and Serves as a Marker of Poor Prognosis in Non-Small Cell Lung Cancer. Med Sci Monit. 2020; 26: e925147.